title: A 9-mo randomized clinical trial comparing fat-substituted and fat-reduced diets in healthy obese men: the Ole Study.
abstract: BACKGROUND
  Dietary fat has been implicated as a risk factor for cardiovascular disease and obesity.
  
  
  OBJECTIVE
  We evaluated the effect on body weight, body fat, lipids, glucose, and insulin of replacing dietary fat with olestra in moderately obese men.
  
  
  METHODS
  Forty-five healthy overweight men were randomly assigned to 1 of 3 diets: control diet (33% fat), fat-reduced diet (25% fat), or fat-substituted diet (one-third of dietary fat replaced by olestra to achieve a diet containing 25% metabolizable fat). Body fat was measured by dual-energy X-ray absorptiometry and visceral and subcutaneous abdominal fat by computed tomography.
  
  
  RESULTS
  Thirty-six men completed the 9-mo study. Body weight and body fat in the fat-substituted group declined by a mean (+/- SEM) of 6.27 +/- 1.66 and 5.85 +/- 1.34 kg, respectively, over 9 mo compared with 3.8 +/- 1.34 and 3.45 +/- 1.0 kg in the control group and 1.79 +/- 0.81 and 1.68 +/- 0.75 kg in the fat-reduced diet group. At 9 mo, the mean difference in body fat between the fat-reduced and fat-substituted groups was -4.19 +/- 1.19 kg (95% CI: -6.57, -1.81), that between the control and fat-substituted groups was -2.55 +/- 1.21 kg (-0.13, -4.97), and that between the control and fat-reduced groups was 1.63 +/- 1.18 kg (3.96, -0.70). The men eating the fat-reduced diet asked for almost no extra foods, in contrast with the significantly higher requests (P < 0.05) from both of the other 2 groups.
  
  
  CONCLUSIONS
  Replacement of dietary fat with olestra reduces body weight and total body fat when compared with a 25%-fat diet or a control diet containing 33% fat.
authors.affiliation: Pennington Biomedical Research Center, Baton Rouge, LA 70808, USA. brayga@pbrc.edu
authors.forename: George A
authors.initials: GA
authors.lastname: Bray
authors.forename: Jennifer C
authors.initials: JC
authors.lastname: Lovejoy
authors.forename: Marlene
authors.initials: M
authors.lastname: Most-Windhauser
authors.forename: Steven R
authors.initials: SR
authors.lastname: Smith
authors.forename: Julia
authors.initials: J
authors.lastname: Volaufova
authors.forename: Yvonne
authors.initials: Y
authors.lastname: Denkins
authors.forename: Lilian
authors.initials: L
authors.lastname: de Jonge
authors.forename: Jennifer
authors.initials: J
authors.lastname: Rood
authors.forename: Michael
authors.initials: M
authors.lastname: Lefevre
authors.forename: Alison L
authors.initials: AL
authors.lastname: Eldridge
authors.forename: John C
authors.initials: JC
authors.lastname: Peters
mesh_terms: D000273:Adipose Tissue / Q000473:pathology; D001823:Body Composition; D001835:Body Weight; D018752:Diet, Fat-Restricted; D019358:Fat Substitutes / Q000627:therapeutic use*; D005227:Fatty Acids / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009765:Obesity / Q000178:diet therapy* / Q000188:drug therapy* / Q000473:pathology; D012016:Reference Values; D013395:Sucrose / Q000031:analogs & derivatives* / Q000627:therapeutic use*
chemical_list: D019358:Fat Substitutes; D005227:Fatty Acids; D013395:Sucrose; C013692:sucrose polyester